Bayer beats earnings estimates but legal wrangles remain

4 August 2022

German life sciences major Bayer (BAYN: DE) beat consensus estimates with its sales in the second quarter of 2022, with the 12.82 billion euros ($13 billion) total representing an 18% rise on the same period in 2021.

Earnings before interest and taxes (EBIT) reached 169 million euros, an improvement on last year’s loss of 2.28 billion euros but still modest due to the company being hit by net special charges of 2.11 billion euros including impairment losses related to its agricultural division.

"Significant gains at Crop Science and strong growth at Consumer Health, as well as a slight increase at Pharmaceuticals"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK